Questions? Contact us.


sidebar-facebook


At Diplomat, we serve our patients with immune globulin products for treatment of primary immune deficiencies and autoimmune-related disorders. We carry a number of major brands and ship them via express delivery anywhere in the United States. Moreover, our clinicians are available to assist you 24 hours per day, 7 days per week.

Intravenous Immune Globulin (IVIg)

  • Flebogamma® 5% DIF [grifols.com]
    Form Liquid
    Distributor Grifols
    Route of administration Intravenous
    FDA indication Primary immunodeficiency (PI) Package Insert
    pH (after reconstitution) 5 – 6
    Concentration 5%
    IgA content <50 μg/mL
    % IgG ≥97%
    Na content Trace amounts
    Diluent N/A
    Osmolality (mOsm/L) 240 – 370
    Initial infusion rate Initial rate of 0.01 mL/kg body weight/min. If tolerated during first 30 minutes, can be gradually increased to a max of 0.1 mL/kg/min.
    Sugar content 5 g D-sorbitol (as stabilizer) in 100 mL of water for injection
    Shelf life 24 months
    Storage requirements Room temperature: 2–25°C (36 to 77°F). Do not freeze.
    Flushing compatibility Saline or dextrose
  • Flebogamma® 10% DIF [grifols.com]
    Form Liquid
    Distributor Grifols
    Route of administration Intravenous
    FDA indication Primary immunodeficiency (PI) Package Insert
    pH (after reconstitution) 5 – 6
    Concentration 10%
    IgA content <100 μg/mL
    % IgG ≥97%
    Na content Trace amounts
    Diluent N/A
    Osmolality (mOsm/L) 240 – 370
    Initial infusion rate 0.01 mL/kg/min (1 mg/kg/min). If tolerated, increase to 0.08 mL/kg/min (8 mg/kg/min).
    Sugar content 5 g D-sorbitol (as stabilizer) in 100 mL of water for injection
    Shelf life 24 months
    Storage requirements Room temperature: 2–25°C (36 to 77°F). Do not freeze.
    Flushing compatibility Saline or dextrose
  • Gammagard® S/D IgA <1 μg/mL [gammagard.com]
    Form Lyophilized
    Distributor Shire
    Route of administration Intravenous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP), bacterial infection associated with B-cell Chronic Lymphocytic Leukemia (CLL), Kawasaki Syndrome. Package Insert
    pH (after reconstitution) 6.8 ± 0.4
    Concentration 5% (for 10%, use half of supplied diluent)
    IgA content <1 μg/mL
    % IgG ≥90%
    Na content 85 mg/mL with 5% solution
    Diluent Sterile Water (96 mL for 5 gm 5%, 192 mL for 10 gm 5%)
    Osmolality (mOsm/L) 636 (5%), 1250 (10%)
    Initial infusion rate:
    • 5 solution%: 0.5 mL/kg/hr (0.8 mg/kg/min). Can gradually increase every 30 minutes to a rate of 4 mL/kg/hr.
    • 10% solution: If 4 mL/kg/hr is tolerated, can increase to 10% solution starting at 0.5 mL/kg/hr to a max of 8mL/kg/hr.
    Sugar content 20 mg/mL glucose with 5%
    Shelf life 24 months
    Storage requirements Room temperature: up to 25ºC (77ºF). Freezing should be avoided to prevent the diluent bottle from breaking.
    Flushing compatibility Saline or dextrose
    Patient support/assistance programs Gammagard Patient Support Program,MyIgSource
    Other websites ImmuneDisease.com
  • Gammagard® Liquid [gammagard.com]
    Form Liquid
    Distributor Shire
    Route of administration Intravenous or Subcutaneous
    FDA indication Primary immunodeficiency (PI), Multifocal motor neuropathy (MMN). Package Insert
    pH (after reconstitution) 4.6–5.1
    Concentration 10%
    IgA content 37 μg/mL
    % IgG ≥98%
    Na content No added sodium
    Diluent N/A
    Osmolality (mOsm/L) 240–300
    Initial infusion rate (IV only)
    • PIDD: 0.5 mL/kg/hr (0.8 mg/kg/min) for 30 minutes.
    • MMN: 0.5 mL/kg/hr (0.8 mg/kg/min).
    Initial infusion rate (SC only)
    • PIDD:
      • ≥40 kg body weight: 30 mL/site at 20 mL/hr/site.
      • <40kg: 20 mL/site at 15 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 24 months at room temperature. Package Insert
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Saline or dextrose
    Patient support/assistance programs:
    Other websites ImmuneDisease.com
  • Gammaked™ [gammaked.com]
    Form Liquid
    Distributor Kedrion Biopharma
    Route of administration Intravenous or Subcutaneous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Package Insert
    pH (after reconstitution) 4 – 4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content 1.3 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only):
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
  • Gammaplex® [gammaplex.com]
    Form Liquid
    Distributor Bio Products Laboratory
    Route of administration Intravenous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP). Package Insert
    pH (after reconstitution) 4.8 – 5.1
    Concentration 5%
    IgA content <10 μg/mL
    % IgG >95%
    Na content 0.3 g NaCl
    Diluent N/A
    Osmolality (mOsm/L) ≥240 (typically 420 – 500)
    Initial infusion rate (IV only) 0.5 mg/kg/min (0.01 mL/kg/min for 15 minutes, then gradually increase to 4mg/kg/min. (0.08 mL/kg/min).
    Sugar content 5 g D-sorbitol in 100 mL of buffer solution
    Shelf life 36 months
    Storage requirements Room temperature: 2–25°C (36–77°F). Do not freeze. Protect from light.
    Flushing compatibility Saline or dextrose
  • Gammaplex® 10%
    Form Liquid
    Distributor Bio Products Laboratory
    Route of administration Intravenous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP). Package Insert
    pH (after reconstitution) 4.9 – 5.2
    Concentration 10%
    IgA content <20 μg/mL
    % IgG ≥98%
    Na content <30 mmol/100mL NaCl
    Diluent N/A
    Osmolality (mOsm/L) ≥240 mOsmol/kg (typically 280)
    Max infusion rate 0.08 mL/kg/min
    Sugar content No added sugars
    Shelf life 36 months
    Storage requirements Room temperature: 2–25°C (36–77°F). Do not freeze. Protect from light.
  • Gamunex®-C [gamunex-c.com]
    Form Liquid
    Distributor Grifols
    Route of administration Intravenous or Subcutaneous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Package Insert
    pH (after reconstitution) 4–4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content Trace amounts (<7 mEq/L)
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only)
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
    Patient support/assistance program Gamunex Connexions
  • Octagam® 5% [octagamus.net]
    Form Liquid
    Distributor Octapharma
    Route of administration Intravenous
    FDA indication Primary immunodeficiency (PI). Package Insert
    pH (after reconstitution) 5.1 – 6
    Concentration 5%
    IgA content ≤200 μg/mL
    % IgG ≥96%
    Na content <30 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 310–380
    Initial infusion rate (IV only) Initial rate of 0.5 mg/kg/min.
    Sugar content 100 mg/mL maltose*
    Shelf life 24 months
    Storage requirements Room temperature: 2–25°C (36–77°F). Do not freeze.
    Flushing compatibility Saline or Dextrose
    * Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ] or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in Octagam liquid as glucose. This has resulted in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering Octagam liquid, the measurement of blood glucose must be done with a glucose-specific method. The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products.
  • Octagam® [octagamus.net]
    Form Liquid
    Distributor Octapharma
    Route of administration Intravenous
    FDA indication Chronic immune thrombocytopenic purpura (ITP) Package Insert.
    pH (after reconstitution) 4.5–5
    Concentration 10%
    IgA content 106 μg/mL (average)
    % IgG ≥96%
    Na content (at 5% concentration) <30 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 310–380 mOsmol/kg
    Initial infusion rate 1.0 mg/kg/min (0.01 mL/kg/min)
    Maintenance Infusion Rate (if tolerated) Up to 12.0 mg/kg/min (Up to 0.12 mL/kg/min)
    Sugar content 90 mg/mL maltose*
    Shelf life 24 months (refrigerated). Within the first 12 months of its shelf life, the product may be stored up to 9 months at ≤+25°C (77°F).
    Storage requirements Room temperature: 2–25°C (36–77°F). Do not freeze. Refrigeration: 2°–8°C (36–46°F).
    * Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ] or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in Octagam liquid as glucose. This has resulted in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering Octagam liquid, the measurement of blood glucose must be done with a glucose-specific method. The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products.
  • Privigen® [privigen.com]
    Form Liquid
    Distributor CSL Behring
    Route of administration Intravenous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Package Insert
    pH (after reconstitution) 4.6 – 5
    Concentration 10%
    IgA content <25 μg/mL
    % IgG ≥98%
    Na content Trace amounts
    Diluent N/A
    Osmolality (mOsm/L) 320
    Initial infusion rate (IV only):
    • PIDD: Initial rate of 0.005 mL/kg/min. If tolerated, increase gradually to 0.08 mL/kg/min.
    • ITP: Initial rate of 0.005 mL/kg/min. If tolerated, increase gradually to 0.04 mL/kg/min.
    Sugar content No added sugars
    Shelf life 36 months (room temperature)
    Storage requirements Room temperature: up to 25°C (77°F). Do not freeze. Protect from light.
    Flushing compatibility Saline or Dextrose
    Patient assistance/support programs CSL Behring Patient Assistance Program, CSL Behring Assurance Program
    Other websites TreatingPI.com, IgIQ

Subcutaneous Immune Globulin (SCIg)

  • Cuvitru™ [cuvitru.com]
    FormLiquid
    DistributorShire
    Route of administrationSubcutaneous
    FDA IndicationPrimary immunodeficiency (PI) Package Insert
    pH4.6 to 5.1
    Concentration20%
    IgA content80 mcg/mL
    % IgG≥98%
    Na contentNon-detectable
    DiluentN/A
    Osmolality (mOsm/L)280-292
    Initial infusion rateDo not administer intravenously or intramuscularly. For the first two infusions, the manufacturer’s recommended infusion rate is 10-20 mL/hr/site. For subsequent infusions, the infusion rate may be increased to 60 mL/hr/site as tolerated (e.g., 60 mL/hr/site x 2 sites = 120 mL/hr). For patients utilizing 4 infusion sites, the maximum infusion rate for all sites combined is 240 mL/hr.
    Sugar contentNo added sugars
    Shelf life36 months (refrigerated). 12 months (at room temperature within the first 24 months of date of manufacture).
    Storage requirementsProtect from light. Store in the refrigerator (36°F to 46°F [2°C to 8°C]) for up to 36 months or at room temperature (up to 77°F [25°C]) for up to 12 months.
    Patient assistance/support programsMyIgSource.com
    Other websitesImmuneDisease.com
  • Gammagard® Liquid [gammagard.com]
    Form Liquid
    Distributor Shire
    Route of administration Intravenous or Subcutaneous
    FDA indication Primary immunodeficiency (PI), Multifocal motor neuropathy (MMN). Package Insert
    pH (after reconstitution) 4.6–5.1
    Concentration 10%
    IgA content 37 μg/mL
    % IgG ≥98%
    Na content No added sodium
    Diluent N/A
    Osmolality (mOsm/L) 240–300
    Initial infusion rate (IV only)
    • PIDD: 0.5 mL/kg/hr (0.8 mg/kg/min) for 30 minutes.
    • MMN: 0.5 mL/kg/hr (0.8 mg/kg/min).
    Initial infusion rate (SC only)
    • PIDD:
      • ≥40 kg body weight: 30 mL/site at 20 mL/hr/site.
      • <40kg: 20 mL/site at 15 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 24 months at room temperature. Package Insert
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Saline or dextrose
    Patient support/assistance programs:
    Other websites ImmuneDisease.com
  • Gammaked™ [gammaked.com]
    Form Liquid
    Distributor Kedrion Biopharma
    Route of administration Intravenous or Subcutaneous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Package Insert
    pH (after reconstitution) 4 – 4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content 1.3 mmol/L
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only):
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
  • Gamunex®-C [gamunex-c.com]
    Form Liquid
    Distributor Grifols
    Route of administration Intravenous or Subcutaneous
    FDA indication Primary immunodeficiency (PI), Idiopathic Thrombocytopenic Purpura (ITP), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Package Insert
    pH (after reconstitution) 4–4.5
    Concentration 10%
    IgA content 46 μg/mL
    % IgG ≥98%
    Na content Trace amounts (<7 mEq/L)
    Diluent N/A
    Osmolality (mOsm/L) 258
    Initial infusion rate (IV only)
    • ITP: 1 mg/kg/min.
    • PIDD: 1 mg/kg/min.
    • CIDP: 2 mg/kg/min.
    Initial infusion rate (SC only)
    • PIDD: 20 mL/hr/site.
    Sugar content No added sugars
    Shelf life 36 months (refrigerated). 6 months (at room temperature for up to 6 months anytime during 36 month shelf life).
    Storage requirements Refrigeration: 2–8°C (36–46°F). Room temperature: up to 25°C (77°F). Do not freeze.
    Flushing compatibility (IV only) Dextrose (incompatible with saline)
    Patient support/assistance program Gamunex Connexions
  • Hizentra® [hizentra.com]
    Form Liquid
    Distributor CSL Behring
    Route of administration Subcutaneous
    FDA indication Primary immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Package Insert
    pH (after reconstitution) 4.6 – 5.2
    Concentration 20%
    IgA content ≤50 μg/mL
    % IgG ≥98%
    Na content Trace
    Diluent N/A
    Osmolality (mOsm/L) 380 mOsmol/kg
    Initial infusion rate (IV only) Not for intravenous administration. Avoid injection into blood vessel. Injection sites: abdomen, thighs, upper arms, and/or lateral hip. Manufacturer recommends 15 mL volume per infusion site at a max rate of 50 mL/hr/site by infusion pump.
    Sugar content No added sugars
    Shelf life 30 months (room temperature)
    Storage requirements Room temperature: up to 25°C (77°F). Do not freeze. Protect from light.
    Patient assistance/support programs CSL Behring Patient Assistance Program, CSL Behring Assurance Program
    Other websites TreatingPI.com, IgIQ
  • HyQvia™ [HyQvia.com]
    Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase Form Liquid
    Distributor Shire
    Route of administration Subcutaneous
    FDA indication Primary immunodeficiency (PI). Package Insert
    pH
    • Immune Globulin Infusion 10% (Human): 4.6 – 5.1
    • Recombinant Human Hyaluronidase: 7.4
    Concentration 10%
    IgA content 37 μg/mL
    Na content 8.5 mg/mL NaCl
    % IgG ≥98%
    Diluent N/A
    Osmolality
    • Immune Globulin Infusion 10% (Human): 240 – 300 mOsmol/kg
    • Recombinant Human Hyaluronidase: 290 to 350 mOsm
    Initial infusion rate (SC only)
    • Administer the Recombinant Human Hyaluronidase of HYQVIA at an initial rate per site of approximately 1 to 2 mL per minute, or as tolerated.
    • Administer Immune Globulin Infusion 10% (Human) of HYQVIA at rates provided inpackage insert.
    Shelf life Up to 36 months refrigerated (36° to 46°F). Up to 3 months during the first 24 months at room temperature (77°F) from the date of manufacturing (Mfg date) printed on the carton.
    Storage requirements Refrigeration (36° to 46°F) for up to 36 months. Room temperature (up to 77°F) for up to 3 months. Do not freeze. Protect from light.
    Patient assistance/support programs MyIgSource
    Other websites ImmuneDisease.com


Twitter